STAT+: During the pandemic, were great vaccines bad business? A company-by-company review
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people…
Category: Sanofi
STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived
A U.S. appeals court revived a controversial lawsuit brought by nearly two dozen people who…
STAT+: At health care’s biggest investor conference, AI’s high hopes collided with skepticism
You didn’t need machine learning to make one prediction about the year’s biggest conference for…
Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future
Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally…
Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it?
NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their…
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure
Here are two things that are true. The world needs more effective flu vaccines. And…
STAT+: Why Sanofi got shellacked
Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion…
Pfizer RSV vaccine wins recommendation for seasonal use only
Pfizer’s new shot to protect infants against respiratory syncytial virus by vaccinating their mothers late…
Opinion: STAT+: Sanofi CEO Paul Hudson: The right way to bring AI into pharma
While it’s widely accepted that the pharma industry is innovative in R&D, it is also…